Octreotide
1
Reactions 1214 - 9 Aug 2008 Octreotide Nausea, cholelithiasis and glucose intolerance: case report A 15-year-old boy developed nausea during treatment with octreotide, and then cholelithiasis and glucose intolerance during treatment with octreotide long-acting release (LAR), for growth hormone (GH) suppression. The boy, who had McCune-Albright disease and pituitary gigantism, starting receiving SC octreotide 100µg [dosage not clearly stated] * and bromocriptine at the age of 10 years. The therapy did not successfully suppress GH, and the octreotide injection often caused nausea [time to onset not stated], leading to poor compliance. Therefore, when the boy was 12.3 years old, his therapy was changed to monthly IM octreotide-LAR injections (10mg). No adverse effects were observed, so the dose was increased to 20mg. At the age of 13.4 years, following surgery (second neurological decompression of the left optic nerve), cabergoline was added. At the age of 15.7 years, gallstones were identified and an oral glucose tolerance test revealed impaired glucose tolerance (fasting capillary blood glucose 87 mg/dL and a 120min value of 224 mg/dL). The octreotide- LAR dose was reduced to 10mg and the cabergoline dosage was increased [patient outcome not stated]. Author comment: "[I]mpaired glucose tolerance and gallstones probably due to octreotide-LAR were observed after 3-year treatment." * abstract states 100µg × 2/day, but full case mentions daily injections, and SC injection of octreotide 100µg Tajima T, et al. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. Endocrine Journal 55: 595-599, No. 3, Jun 2008 - Japan 801117341 1 Reactions 9 Aug 2008 No. 1214 0114-9954/10/1214-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Octreotide
Reactions 1214 - 9 Aug 2008
Octreotide
Nausea, cholelithiasis and glucose intolerance:case report
A 15-year-old boy developed nausea during treatment withoctreotide, and then cholelithiasis and glucose intoleranceduring treatment with octreotide long-acting release (LAR), forgrowth hormone (GH) suppression.
The boy, who had McCune-Albright disease and pituitarygigantism, starting receiving SC octreotide 100µg [dosage notclearly stated]* and bromocriptine at the age of 10 years. Thetherapy did not successfully suppress GH, and the octreotideinjection often caused nausea [time to onset not stated],leading to poor compliance.
Therefore, when the boy was 12.3 years old, his therapy waschanged to monthly IM octreotide-LAR injections (10mg). Noadverse effects were observed, so the dose was increased to20mg. At the age of 13.4 years, following surgery (secondneurological decompression of the left optic nerve),cabergoline was added. At the age of 15.7 years, gallstoneswere identified and an oral glucose tolerance test revealedimpaired glucose tolerance (fasting capillary blood glucose87 mg/dL and a 120min value of 224 mg/dL). The octreotide-LAR dose was reduced to 10mg and the cabergoline dosagewas increased [patient outcome not stated].
Author comment: "[I]mpaired glucose tolerance andgallstones probably due to octreotide-LAR were observed after3-year treatment."
* abstract states 100µg × 2/day, but full case mentions daily injections,and SC injection of octreotide 100µg
Tajima T, et al. Case study of a 15-year-old boy with McCune-Albright syndromecombined with pituitary gigantism: effect of octreotide-long acting release (LAR)and cabergoline therapy. Endocrine Journal 55: 595-599, No. 3, Jun 2008 -Japan 801117341
1
Reactions 9 Aug 2008 No. 12140114-9954/10/1214-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
